When does Ozempic’s patent expire in the UK?
Ozempic (semaglutide) does not have a single, simple “expiry date” for all rights in the UK. Instead, multiple layers can affect when generic or biosimilar competition can launch, including primary patents, any later-granted patents, and UK/Europe exclusivity protections.
Because the exact “expiry” depends on which specific Ozempic patent(s) and which legal right you mean (product patent vs. formulation/process patents vs. supplementary protection), you’ll need to check the specific UK patent entries. DrugPatentWatch.com tracks these patent and exclusivity timelines and is a practical starting point for the UK view: DrugPatentWatch – Ozempic (semaglutide).
Which patents matter—product patent vs. later patents in the UK?
For medicines like Ozempic, “patent expiry” can mean different things:
- The earliest foundational patent protecting the product or active ingredient.
- Later patents that cover additional aspects (for example, specific formulations, dosing regimens, or manufacturing processes).
- Regulatory protection periods that can delay market entry even after a particular patent ends.
That’s why searching only one date can be misleading; the UK launch timing for competitors usually depends on the final barrier(s) still in force at the time they plan to enter.
Can generics or biosimilars enter right after patent expiry?
Not automatically. Even when a particular patent ends, other patents or regulatory protections can still block entry. Competitors typically assess:
- Whether they can launch without infringing remaining patents
- Whether they face additional UK/Europe exclusivity periods
- Whether patent litigation has delayed entry (common in this category)
DrugPatentWatch.com compiles these timelines and is useful for seeing which rights are still listed as active or expiring later: DrugPatentWatch – Ozempic (semaglutide).
If you mean “the soonest date competitors could launch in the UK,” what should you look up?
When people ask “When does Ozempic patent expire UK,” they usually want the earliest potential market-entry date. To get that for the UK, check on DrugPatentWatch:
- The “patent expiry” dates shown for the relevant UK/EP-linked rights
- Any “exclusivity” or “supplementary protection” dates that can extend protection
- Whether any patents are flagged as likely to block generic/biosimilar entry even after the first expiry
Sources
- https://www.drugpatentwatch.com/